Guest guest Posted February 2, 2001 Report Share Posted February 2, 2001 Anyone know anything more about the paragraph below? If true, this could be a bit of good news..... > >Enhanced proliferation and potassium conductance of Schwann cells >isolated from NF2 schwannomas can be reduced by quinidine. > >Rosenbaum C, Kamleiter M, Grafe P, Kluwe L, Mautner V, Muller HW, Hanemann CO > >Department of Neurology, Heinrich-Heine University, Duesseldorf, Germany. > >Neurofibromatosis type 2 (NF2) is an autosomal dominant disease that >is characterized mainly by schwannomas, as well as menigiomas and >gliomas. The NF2 gene product merlin/schwannomin acts as a tumor >suppressor. Schwann cells derived from NF2 schwannomas showed an >enhanced proliferation rate, and electrophysological studies >revealed larger K(+) outward currents as compared with controls. >Schwann cells isolated from schwannomas of NF2 patients or >multiorgan donors were treated with different concentrations of the >K(+) current blockers quinidine, tetraethylammonium chloride, and >4-aminopyridine and K(+) outward currents and proliferation rates of >these cells were compared. K(+) outward currents of both cell types >can be blocked by quinidine. Importantly, treatment with quinidine >reduces proliferation of NF2 Schwann cells in a concentration >dependent manner but did not reduce proliferation of normal Schwann >cells. Therefore, the use of quinidine or quinidine-like components >would! > possibly provide a novel adjuvant therapeutic option for NF2 >patients to slow down or freeze growth of schwannomas. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.